Capstar Special Purpose Acquisition Files S-4 on $1B Gelesis Deal


Capstar Special Purpose Acquisition filed a preliminary proxy on Form S-4 outlining terms of its proposed merger with Gelesis, a biotherapeutics company focused on weight loss treatments and metabolic disorders. The deal has a pro forma implied market value of approximately $1.3 billion and enterprise value of approximately $1 billion.

The transaction would provide up to $376 million in gross proceeds to the combined company from a combination of a $100 million PIPE and $276 million of cash held in Capstar’s trust account (assuming no redemptions). The PIPE financing is anchored by a mix of new and existing investors and partners, including PIMCO private funds, Pritzker Vlock Family Office, China Medical Systems Holdings and co-founder PureTech Health. Kennedy Lewis Investment Management will invest $10 million in the PIPE conditioned upon the closing of their $100 million senior-secured credit facility to the company.

Gelesis’ existing shareholders will convert 100% of their ownership stakes into the new company. 

If approved, upon completion the combined company’s securities are expected to trade on the NYSE under GLS. Read more.

Related Posts
Novus Capital II
Read More

Novus Capital II Closes $287.5M IPO

The SPAC said it would target “smart technologies, 5G communication, virtual reality, artificial intelligence, spatial computing, cloud analytics, machine learning, hardware and software distribution, value added customized logistics services, sustainable smart city systems and sustainable agricultural technology, or AgTech.”